EN | TR
E-ISSN: 3061-9947
Non-transitional Cell Carcinoma of The Bladder: Single Center Experience
PDF
Cite
Share
Request
Original Article
VOLUME: 50 ISSUE: 3
P: 187-194
2017

Non-transitional Cell Carcinoma of The Bladder: Single Center Experience

Acta Haematol Oncol Turc 2017;50(3):187-194
DOI: 10.5505/aot.2017.83007
Gökmen Umut Erdem
Mutlu Doğan
Nebi Serkan Demirci
Yakup Bozkaya
Doğan Uncu
Nurullah Zengin
1. Ankara Training and Research Hospital, Medical Oncology, Ankara, Turkey
2.
No information available.
No information available
Received Date: 2017-08-18T02:56:26
Accepted Date: 2017-12-19T11:05:57
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Because non-transitional bladder cancers are rare, there is a few data in the literature. For this purpose, patients were evaluated retrospectively in terms of clinicopathologic characteristics, treatment modalities, and their prognostic effects.

METHODS

Thirty patients with pure non-urothelial bladder cancer, who were followed between October 2004 and September 2015, were evaluated retrospectively.

RESULTS

Out of 390 consecutive patients with bladder cancers, 30 had pure non-urothelial carcinoma (7.6%): %3.9 SqCC, %2.0 AC, %1.0 SmCC, %0.7 another non-urothelial carcinoma. The median age of the patients was 60 years (range, 22–82 years) and the male/female ratio was 4: 1 (24 males and 6 females). The most common symptom was macroscopic hematuria (73.3%). Seven patients (23.3%) had stage II disease, ten patients (33.3%) had stage III disease and thirteen patietns (43.3%) had stage IV disease. The median follow-up period was 10.0 months, during which 80.0% experienced recurrence/progression, and 76.7% died. The median overall survival (OS) was 10.0 months and there was no significant difference in terms of histopathological subtypes (P=0.30). The median OS of seventeen patients with stage 2-3 was 13.1 months. The median survival for stage I–III patients treated with surgery±CT ±RT (median OS yet not reached) was longer than for those treated with TUR ± CT ± RT (10 months) (P = 0.07). Univariate analysis revealed that younger age (P=0.04), stage 2-3 disease (P=0.02), ECOG performance status<2 (P=0.04), and the absence of metastasis (P=0.04) were factors indicating a good prognosis.

DISCUSSION AND CONCLUSION

In patients with non-urothelial cancer, there was no overall survival difference between groups in terms of histopathological subtypes. At the time of diagnosis, younger age, stage 23 disease, ECOG performance status<2, and the absence of metastasis were factors indicating a good prognosis. Surgery ± CT ± RT resulted in significantly better OS, except for in patients with stage 4 disease.